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Concise report
Interferon a kinoid induces neutralizing anti-
interferon a antibodies that decrease the expression
of interferon-induced and B cell activation
associated transcripts: analysis of extended follow-
up data from the interferon a kinoid phase I/II study
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Abstract
Objective. IFN a Kinoid (IFN-K) is a therapeutic vaccine composed of IFNa2b coupled to a carrier protein.
In a phase I/II placebo-controlled trial, we observed that IFN-K significantly decreases the IFN gene
signature in whole blood RNA samples from SLE patients. Here, we analysed extended follow-up data
from IFN-K-treated patients, in order to evaluate persistence of neutralizing anti-IFNa Abs antibodies
(Abs), and gene expression profiling.
Methods. Serum and whole blood RNA samples were obtained in IFN-K-treated patients included in the
follow-up study, in order to determine binding and neutralizing anti-IFNa Ab titres, and perform high-
throughput transcriptomic studies.
Results. Neutralization studies of 13 IFNa subtypes demonstrated the polyclonal nature of the Ab re-
sponse induced by IFN-K. Follow-up analyses in six patients confirmed a significant correlation between
neutralizing anti-IFNa Ab titres and decrease in IFN scores compared to baseline. These analyses also
revealed an inhibitory effect of IFNa blockade on the expression of B cell associated transcripts.
Conclusions. IFN-K induces a polyclonal anti-IFNa response that decreases IFN- and B cell-associated
transcripts.
Trial registration: ClinicalTrials.gov, clinicaltrials.gov, NCT01058343
Key words: systemic lupus erythematosus, interferon alpha, interferon alpha kinoid, interferon signature, B
cells.
Rheumatology key messages
. IFNa kinoid induces a polyclonal anti-IFNa antibody response with a broad neutralizing capacity of IFNa
subtypes.
. IFNa neutralization in SLE patients decreases the expression of genes involved in B cell activation.
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Introduction
IFN a-kinoid (IFN-K) is a therapeutic vaccine composed of
inactivated IFNa2b coupled to a carrier protein. When ad-
ministered to human IFNa transgenic mice, IFN-K induced
a polyclonal antibody (Ab) response that neutralized all 13
human IFNa subtypes, but not IFNb or IFNg [1]. In lupus-
prone NZB/W mice, mouse IFN-K prevented disease
manifestations (death, renal disease) triggered by exogen-
ous IFNa [2].
IFN-K was tested in a placebo-controlled phase I/II
study including 28 SLE patients. We previously reported
our observations up to day 168 after the first IFN-K injec-
tion. IFN-K induced 10 higher anti-IFNa binding Abs in
IFN gene signaturepositive (two/three of the patients)
compared with IFN gene signaturenegative individuals.
In these IFN-signaturepositive patients, IFN-K adminis-
tration resulted in a significant decrease in the expression
of IFN-induced genes, and the amplitude of the inhibition
correlated with binding anti-IFNa Ab titres [3, 4].
Here, we report on the characterization of the neutraliz-
ing anti-IFNa Ab response induced by IFN-K in the phase
I/II-included patients. We also analysed extended follow-
up data obtained in six IFN-Ktreated patients in order to
obtain transcriptomic and biological insights into the long-
term effects of the drug.
Patients and methods
Twenty-eight patients with SLE (aged 1850 years),
according to the ACR criteria for SLE [5], were recruited
in a multicentre, randomized, double-blind placebo-
controlled, phase I/II staggered dose-escalation trial of
IFN-K (ClinicalTrials.gov registry number NCT01058343).
Patients were randomized to receive three or four injec-
tions of placebo (n = 7) or 30 mg (n = 3), 60 mg (n = 6), 120mg
(n = 6) or 240mg (n = 6) IFN-K. Clinical and safety data,
induction of anti-IFNa Ab and gene expression profiling
studies for up to day 168 after the first IFN-K injection
were reported previously [3]. Institutional ethics commit-
tee approval for the present follow-up study was obtained
for all participating centres. All subjects provided written
informed consent.
Follow-up sera were obtained every 3 months after the
last study visit in a majority of patients, up to day 336 in
placebo-treated, and up to day 1558 in IFN-K treated pa-
tients. In six patients, whole blood samples were collected
in PAXgene Blood RNA tubes (Qiagen, Courtaboeuf,
France) every 6 months during follow-up, together with
biological (binding and neutralizing anti-IFNa Ab titres,
C3 concentrations and anti-ds DNA Ab titres) data (see
supplementary Table S1 and supplementary materials
and methods, available at Rheumatology Online). RNA
was extracted from these samples, and was also re-ex-
tracted from baseline (month 0) and day 168 (month 6)
PAXgene tubes stored at 80 from the same patients,
and from 10 healthy volunteers (described in [3]). RNA
extraction and hybridization of HGU133 Plus2.0 arrays
(Affymetrix, High Wycombe, UK) are described in the sup-
plementary material and methods, available at
Rheumatology Online. The Affymetrix.CEL files were de-
posited in the Gene Expression Omnibus of the National
Center for Biotechnology Information, and are accessible
through Gene Expression Omnibus accession number
GSE72754.
Analysis of the gene expression data was performed on
GeneSpring (Agilent, Santa Clara, CA) after normalization
by robust multi-array analysis [6]. In order to mine our
microarray data, we looked at correlations between
serum neutralizing anti-IFNa Ab titres and differences in
gene expression compared with baseline. We used several
time points from the same patients, in view of the strong
changes in anti-IFNa Ab titres over time, to increase the
sensitivity of our analyses. Pathway analyses were done
using DAVID [7, 8]. Calculation of the IFN [9] and B cell
scores are described in the supplementary materials and
methods, available at Rheumatology Online. Statistical ana-
lyses were performed on Prism v5.0 software. Correlations
with serum neutralizing anti-IFNa Ab titres were evaluated
using non-parametric tests (Spearman r). Between-group
differences in B cell score evolution over time was evalu-
ated using a KruskalWallis test. Additional gene set en-
richment analyses were performed using all samples from
the initial IFN-K trial (GSE39088), as well as samples from
10 SLE patients with nephritis, before administration of im-
munosuppressive therapy (GSE72747), IFNa-stimulated
control whole blood cells (GSE39088) and CpG-stimulated
purified B cells from healthy individuals (GSE45113). [10] A
description of these samples is provided in supplementary
Table S2, available at Rheumatology Online.
Results
As described previously, 10 out of 21 patients who
received IFN-K (mainly in the 120 and 240 mg groups) de-
veloped neutralizing anti-IFNa Abs, which were still de-
tectable in 6 of them at last follow-up visit (range of
persistence: 1681558 days, see supplementary Fig. S1,
available at Rheumatology Online). Neutralization studies
on 13 different IFNa subtypes were performed using sera
from 2 IFN-Ktreated patients, and compared with the
neutralization pattern of 9F3, an anti-IFNa2b mAb. The
results displayed in supplementary Table S3, available at
Rheumatology Online, confirmed the polyclonal nature of
the neutralizing Ab response induced by IFN-K.
Extended follow-up data were collected in 6 out of the
21 IFN-Ktreated patients. One of them (in the 240mg
group) did not have a positive IFN gene signature at base-
line. In the five other patients, normalization of the IFN
signature was observed in two of them who had de-
veloped moderate or high titres neutralizing anti-IFNa anti-
bodies (Fig. 1A). Accordingly, there was a significant
correlation between serum neutralizing anti-IFNa Ab
titres and decreased expression of IFN-induced genes
(Fig. 1B). There was also a moderate correlation between
increase in serum C3 and neutralizing anti-IFNa Ab titres,
but the P-value was not significant (r = 0.32, P = 0.054)
(Fig. 1C). Serum anti dsDNA Ab titres increased in one
patient who did not develop neutralizing anti-IFNa Abs,
and were stable in all other patients (Fig. 1D).
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In these 6 patients, serum anti-IFNa neutralizing anti-
body titres displayed a strong (0.9< r <0.7) negative
correlation with decreased expression of 156 transcripts
(supplementary Table S4, available at Rheumatology
Online). Pathway analyses showed that these transcripts
were significantly enriched in immunoglobulin genes
(supplementary Table S5, available at Rheumatology
Online). Gene set enrichment analyses showed that the
majority of them were overexpressed in SLE patients
compared with in controls. These transcripts were also
induced by IFNa in control cells, thereby confirming that
they are IFNa-dependent. Finally, many of them were
FIG. 1 Effects of neutralizing anti-IFNa Abs on the expression of IFN-induced genes
(A) Mean-centred, log2-transformed normalized expression of 21 IFN-induced probe sets (green square =2.5; red
square = +2.5) used to calculate IFN scores (probe set identifications are displayed in supplementary Table S7), IFN
scores and serum anti-IFNa Ab titres (U/ml) in 10 controls and 6 IFN-Ktreated SLE patients are displayed at the
indicated time points, at which transcriptomic, biological and serological data were available. (B) Correlation between
log10-transformed serum neutralizing anti-IFNa Abs and changes in IFN scores compared with baseline or (C) changes in
serum C3 compared with baseline. (D) Evolution of serum dsDNA Ab titres at the same time points. Spearman  cor-
relation coefficients are displayed on the graphs. Patients’ study numbers: filled square = 030501; open circle = 030402;
filled circle = 060102; filled rhombus = 010101; filled inverted triangle = 030401; filled triangle = 060101.
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induced in proliferating CD27high B cells stimulated with a
TLR9 agonist, which confirmed their potential link with B
cell activation processes (Fig. 2A).
We designed a score using the 10 (out of 156 listed
above) transcripts that were most overexpressed in
C27high CpG-stimulated B cells (Fig. 2A, supplementary
Table S6, available at Rheumatology Online). Not surpris-
ingly, decrease in the CpG-stimulated B cell score corre-
lated significantly with serum anti-IFNa neutralizing Ab
titres in the extended follow-up group of patients
(Fig. 2B). Because the observed correlation was driven
by two patients with high neutralizing Ab titres, we re-
turned to the original phase I/II trial data on all patients
in order to increase sample size. We found that IFN-K
significantly decreased the expression of these transcripts
at day 112 and at day 168 in patients with a positive IFN
signature at baseline, compared with IFN signature
negative or placebo-treated patients (Fig. 2C).
Discussion
Extended follow-up data from SLE patients included in the
phase I/II IFN-K trial demonstrate that IFN-K induces not
only binding, but also neutralizing anti-IFNa Abs, mainly in
the higher dose groups. The neutralizing response is poly-
clonal and extends to numerous IFNa subtypes. Inhibition
FIG. 2 Genes downregulated by IFN-K are significantly enriched in B cellassociated transcripts
Serum neutralizing anti-IFNa Ab titres display a strong (0.9 < r<0.7) correlation with decreased expression of 156
transcripts (compared with baseline) in 6 IFN-Ktreated SLE patients observed during the extended follow-up period.
(A) Radar plot showing the relative expression of these 156 transcripts in the indicated experimental conditions. The B
cell score is calculated using the 10 most differentially expressed genes in proliferating CpG-stimulated B cells.
(B) Correlation between log10-transformed serum neutralizing anti-IFNa Abs and changes in B cell scores compared
with baseline. Patients’ study numbers: filled square = 030501; open circle = 30402; filled circle = 060102; filled
rhombus = 010101; filled inverted triangle = 030401; filled triangle = 060101. (C) Box plots (median, interquartile range,
10th and 90th percentiles) showing the changes from day 0 in the expression of the 10 probe sets used in the B cell score
in all patients included in the phase I/II trial. The differences in the average log2 expression of each of these probe sets
between the indicated day and day 0 were calculated for patients treated with placebo (n = 7), IFN signaturenegative
(n = 7) and IFN signaturepositive (n = 12) patients treated with IFN-K. *P < 0.05 using the KruskalWallis tests.
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of the IFN signature correlates with serum neutralizing
anti-IFNa Abs. In addition, in vivo IFNa neutralization is
associated with decreased expression of transcripts
associated with B cell activation in peripheral blood, an
observation that we could extend from the small subset of
patients included in the extended follow-up, to the whole
population of IFN-Ktreated patients.
More efficient target neutralization by a polyclonal,
rather than a monoclonal antibody response is a well-
established concept, and experimental evidence confirms
the synergistic blocking effects of a mix, compared with
single mAbs [11]. In the case of IFNa, the ability of such
monoclonal Abs to inhibit each individual subtype is vari-
able, and it is possible that some in vivo IFNa activity re-
mains even under therapy. The observation that
rontalizumab induces clinical improvement in patients
with little or no in vivo IFNa bioactivity, but not in patients
with higher levels, is further indirect support in favour of
this hypothesis [12]. In contrast, the polyclonal anti-IFNa
response induced by IFN-K enhances the probability of
neutralization of all IFNa subtypes. In addition, production
of higher titres of anti-IFNa Abs in IFN signaturepositive
patients results in IFN-blocking activity, even in patients
with elevated IFNa bioactivity [3].
Further data mining indicated that IFN-Kinduced anti-
IFNa Abs decreased the expression of immunoglobulin
and other B cellassociated transcripts. This observation
is in line with the known direct and indirect effects of IFNa
on B cell activation and differentiation [13]. Whether this
effect of IFN-K on circulating B cells will affect activity and
size of the autoAb-producing pool of long-lived plasma
cells in lupus will be key in evaluating the disease-
modifying effect of IFNa neutralization in SLE.
In conclusion, these observations confirmed the broad
IFNa-neutralizing ability of IFN-K, and indicate that further
evaluation of the therapeutic effects of the drug in a large
placebo-controlled trial is warranted.
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